Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) compared to historical benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) overview

Peripheral arterial disease (PAD) and peripheral vascular disease (PVD) refer to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication); leg numbness or weakness; coldness in lower leg or foot, especially when compared with the other side; sores on toes, feet, or legs that won’t heal; slower growth of toenails; and erectile dysfunction in men.

For a complete picture of PTSR and LoA scores for drugs in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.